IGF1 and Alzheimer disease: Based on the potential role of IGF-1R suppression against AD development and according to our previous data which reported diminished gliosis and Aβ burden in the df/df/AβPP/PS1 transgenic mice which express low levels of brain IGF-1 (Puig et al., 2016), we hypothesized that applying a short-term pharmaceutical intervention might attenuate disease presentation.